Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label active-controlled trial of JW202313 dry powder inhaler in COPD
CTR20261059Phase 2Terminated
- Sponsor
- Shandong Jianwei Pharmaceutical
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of JW202313 in chronic obstructive pulmonary disease (COPD), sponsored by Shandong Jianwei Pharmaceutical. Started Mar 2026; status: terminated.
02
Drugs
JW202313
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20261059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261059.